生物製造市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按工作流程、按应用、最终用户、地区和竞争细分

全球生物製造市场在 2022 年实现估值 190.8 亿美元，并预计在整个预测期内强劲增长，预计复合年增长率 (CAGR) 为 7.72%，预计到 2028 年将达到 296.7 亿美元。生物製造市场涉及生物技术和製药领域，包括生物製品的生产，如生物製药、细胞疗法、基因疗法、疫苗和其他生物衍生产品。这个市场涵盖了从设计和开发到扩大规模和大规模生产的整个活动范围，以满足患者、医疗保健系统和研究工作的需求。生物製造是生物技术和製药行业的关键组成部分，有助于创造拯救生命和增强生命的产品。随着技术和科学知识的不断进步，生物製造领域预计将不断发展，带来新的疗法、改进的生产过程和增强的能力，以满足医疗保健和患者需求日益增长的要求。

主要市场驱动因素

采用先进技术和创新：老年人口的增加和慢性呼吸系统疾病的盛行率预计将推动呼吸器的需求。人们对肺癌症状认识的提高以及医疗机构中患者数量的增加促进了呼吸器市场的大幅增长。然而，重要的是要考虑与机械通气相关的潜在风险，例如感染风险增加和肺损伤。自动化、机器人技术和製程控制系统等先进技术可以简化生物製造流程、减少人为错误并提高整体生产效率。这可以缩短週转时间并提高产能，满足对生物製剂不断增长的需求。生物反应器设计、一次性技术和灵活的製造平台的创新使生产的可扩展性变得更加容易。随着对生物製造产品的需求不断增加，快速扩大生产规模的能力变得至关重要。与传统的批量製程相比，连续製造方法可以实现一致的产品品质、减少浪费并提高资源利用率。这些优势可以推动对生物製造产品的需求。

市场概况
预测期	2024-2028
2022 年市场规模	190.8亿美元
2028 年市场规模	296.7亿美元
2023-2028 年复合年增长率	7.72%
成长最快的细分市场	一次性上游生物製造
最大的市场	北美洲

环境问题日益严重：由于人们对环境问题、污染、水资源短缺和无缝药品製造服务的担忧日益加剧，全球生物製造市场必将成长。此外，在植物中实施下一代生物製造将有助于增加市场需求。此外，采用一次性产品策略将有助于降低成本、最大限度地减少产品污染并提高灵活性，从而推动对下一代生物製造的需求。环保意识的增强和对污染的担忧促使生物製造等行业采取更永续和环保的做法。这包括减少废弃物产生、优化资源利用以及实施清洁製造流程。由于生物製造旨在最大限度地减少其环境足迹，因此对环保生物製造流程和产品的需求预计将会上升。水资源短缺是一个迫切的全球问题，影响着包括生物製造在内的各个产业。实施节水製造流程和回收技术可以帮助缓解水资源短缺问题，同时维持生物製药和其他生物衍生产品的生产。

生物製药企业数量不断增加：在预测期内，下一代生物製造市场的成长预计将受到全球生物製药公司数量不断增加的推动。满足患者需求的先进生物製造需求可能会推动下一代生物製造业的进步。在医学科学进步、不断增长的医疗保健需求和新疗法开发的推动下，全球生物製药产业一直在经历大幅成长。随着越来越多的生物製药公司的出现以及现有生物製药公司扩大其产品线，对高效、可扩展且技术先进的生物製造流程来生产这些创新疗法的需求不断增长。总体而言，生物製药公司数量的不断增加以及满足患者对尖端疗法的需求正在推动下一代生物製造业的进步和成长。随着该行业不断创新和开发先进製造解决方案，它将在塑造医疗保健的未来和改善患者治疗效果方面发挥关键作用。

主要市场挑战

巨额资本支出：生物製造过程涉及复杂且专业的设备、设施和技术，可能需要大量的财务投资。建立生物製造设施或升级现有基础设施需要大量的初始资本投资。这包括建造或翻新专门的无尘室，购买生物反应器、净化设备以及生物製药生产所需的其他复杂工具。生物製造所需的大量资本可能会将资源从研发、行销和业务扩张等其他关键领域转移出去。资源分配方面的挑战可能会影响公司的整体成长策略。高资本支出可能导致製造能力高估或利用不足。如果製造产品的实际需求低于预期，投资可能无法产生预期回报。

缺乏熟练的专业人员：熟练的专业人员的短缺是阻碍生物製造市场成长的重大挑战。生物製造是一个高度专业化的领域，需要各种科学、工程和技术学科的专业知识。熟练专业人员的短缺可能会影响生物製造业务的效率、品质和能力。生物製造过程的复杂性，如细胞培养、发酵、纯化和品质控制，需要专门的专业知识。缺乏熟练的人力资源可能会导致生产时间延迟，从而减缓市场上生物製药和其他生物衍生产品的供应。熟练的专业人员对于在整个製造过程中保持严格的品质控制和保证至关重要。缺乏熟练的专业人员可能会影响产品品质和安全。熟练的专业人员在推动生物製造领域的创新和工艺改进方面也发挥着至关重要的作用。缺乏创新可能会阻碍先进技术的采用并阻碍整体市场的成长。随着生物製药需求的增加，由于缺乏管理和营运新设施所需的熟练人员，公司可能难以扩大其生产能力。

主要市场趋势

连续生物製造的出现：连续生物製造的出现有可能显着推动未来生物製造业的成长。连续生物製造透过实现生物製药和其他生物衍生产品的无缝、不间断生产，代表了对传统批量製程的背离。这种创新方法具有多种优势，可以对效率、灵活性、成本效益和整体市场扩张产生积极影响。连续生物製造允许即时连续监控和调整製程参数。这可以改善製程控制、减少变异性并增强产品一致性，从而提高製程效率并缩短生产时间。与传统的批量系统相比，连续生物製造系统通常更紧凑并且需要更少的物理空间。设施占地面积的减少可以节省成本并提高设施设计和选址的灵活性。连续生物製造可以透过连续运作流程来实现更高的生产能力，从而在无需大幅扩建设施的情况下增加产量。这种增加的产能可以满足对生物製药和其他生物衍生产品不断增长的需求。

下一代生物製造过程的开发：下一代生物製造过程的进步使得能够生产治疗肝肾疾病、癌症和糖尿病等重大疾病的生物药物。此外，一次性生物反应器和生物容器等一次性产品的日益普及，以及私人投资者和政府对下一代生物製造单元开发的财政支持的增加，是全球下一代生物製造市场的关键驱动力。预计这些趋势将在整个预测期内持续存在。

细分市场洞察

应用见解：单株抗体是使用生物製造製程最常生产的产品之一。单株抗体 (mAb) 是一种治疗性蛋白质，旨在针对体内特定抗原，例如癌细胞或免疫系统分子。它们已成为现代医疗不可或缺的一部分，其生产通常涉及生物製造技术。单株抗体广泛用于治疗癌症、自体免疫疾病和传染病等疾病。它们是透过生物製造过程生产的，涉及培养哺乳动物细胞以表达特异性抗体。生物反应器和先进的细胞培养技术通常用于单株抗体的生产。荷尔蒙是成长最快的部分，因为胰岛素、生长激素和促红血球生成素等荷尔蒙也是透过生物製造生产的。这些治疗性蛋白质可治疗荷尔蒙缺乏和其他疾病。生物製造涉及使用重组DNA技术将激素基因插入宿主细胞（例如细菌或酵母）中，然后宿主细胞大量生产激素。用于治疗不断增加的糖尿病和其他激素缺乏相关疾病的激素的生产预计将增加全球对生物製造激素的需求。

工作流程见解：连续的上游生物製造可以实现生物製药的连续稳定生产，消除了传统批次製程的停止-启动性质。这可以提高流程效率、减少停机时间并提高资源利用率。与间歇式製程相比，连续生物反应器的一致环境和受控条件可以带来更高的细胞密度和更高的产品产量。连续生物製造系统通常比传统的批量系统更紧凑，这有助于优化设施空间并降低营运成本。由于减少了可变性和更精确的製程控制，连续製程可以使产品品质更加一致和统一。

区域洞察：北美因其发达和先进的医疗基础设施（包括研究机构、学术中心和医疗设施）而占据市场主导地位。该基础设施支持生物製造活动，并促进学术界、研究组织和产业参与者之间的合作。美国食品药物管理局 (FDA) 等监管机构为生物製药产品的审批和监督制定了严格但明确的指导方针。这种监管专业知识为投资者和消费者提供了对生物製造产品的安全和品质的信心。北美强大的创投生态系统和金融市场为生物製药新创公司和老牌公司提供资金支持，推动创新和研究工作。包括中国和印度在内的亚太地区的生物製造业一直在经历成长，原因包括较低的製造成本、庞大的人才库以及该地区对生物製药的需求不断增加等因素。一些国家积极注重发展生物製造集群和基础设施，以吸引投资、提升生物製药能力。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依工作流程（连续上游生物製造、一次性上游生物製造、下游生物製造）
  • 按应用（单株抗体、荷尔蒙、疫苗、重组蛋白、其他）
  • 按最终用户（生物製药公司、研究机构、CMO/CDMO）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按工作流程
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按工作流程
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按工作流程
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按工作流程
  • 按应用
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲生物製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按工作流程
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非生物製造
  • 沙乌地阿拉伯生物製造
  • 阿联酋生物製造

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球口腔临床营养市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 服务内容
• 最近的发展
• 主要人员
• SWOT分析
  • Illumina Inc.
  • Thermo Fischer Scientific Inc.
  • Oxford Nanopore Technologies plc
  • Agilent Technologies, Inc.
  • BGI
  • PerkinElmer Inc.
  • QIAGEN
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Takara Bio Inc.

第 16 章：策略建议

第 17 章：关于我们与免责声明

The Global Bio-Manufacturing Market achieved a valuation of USD 19.08 Billion in 2022 and is poised for robust growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 7.72% and expected to reach USD 29.67 Billion through 2028. The bio-manufacturing market pertains to the biotechnology and pharmaceutical sector, encompassing the production of biological products such as biopharmaceuticals, cell therapies, gene therapies, vaccines, and other biologically derived products. This market covers the entire spectrum of activities, from design and development to scaling up and large-scale production, to cater to the needs of patients, healthcare systems, and research endeavors. Bio-manufacturing is a pivotal component of the biotechnology and pharmaceutical industry, contributing to the creation of life-saving and life-enhancing products. As technology and scientific knowledge continue to advance, the field of bio-manufacturing is expected to evolve, ushering in new therapies, improved production processes, and enhanced capabilities to meet the growing requirements of healthcare and patient needs.

Key Market Drivers

Adoption of Advanced Technology and Innovation: The increasing geriatric population and prevalence of chronic respiratory disorders are projected to drive ventilator demand. The rise in awareness about lung cancer symptoms and the growing number of patients in medical facilities contribute to substantial growth in the ventilator market. However, it's important to consider potential risks associated with mechanical ventilation, such as increased infection risk and lung damage. Advanced technologies like automation, robotics, and process control systems can streamline biomanufacturing processes, reduce human errors, and enhance overall production efficiency. This can lead to faster turnaround times and increased production capacity, addressing the growing demand for biologics. Innovations in bioreactor design, single-use technologies, and flexible manufacturing platforms allow easier scalability of production. With increasing demand for bio-manufactured products, the ability to rapidly scale up production becomes essential. Continuous manufacturing approaches, as opposed to traditional batch processes, can lead to consistent product quality, reduced waste, and improved resource utilization. These advantages can drive demand for bio-manufactured products.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 19.08 Billion
Market Size 2028	USD 29.67 Billion
CAGR 2023-2028	7.72%
Fastest Growing Segment	Single-Use Upstream Biomanufacturing
Largest Market	North America

Rising Environmental Concerns: The global biomanufacturing market is set to grow due to mounting concerns about environmental issues, pollution, water scarcity, and seamless medication manufacturing services. Additionally, the implementation of next-generation biomanufacturing in plants will contribute to increased market demand. Furthermore, the adoption of a single-use product strategy will facilitate cost reduction, minimize product contamination, and enhance flexibility, driving demand for next-generation biomanufacturing. Heightened environmental awareness and worries about pollution have prompted industries, including biomanufacturing, to adopt more sustainable and environmentally friendly practices. This includes reducing waste generation, optimizing resource usage, and implementing cleaner manufacturing processes. As biomanufacturing aims to minimize its environmental footprint, the demand for eco-friendly biomanufacturing processes and products is expected to rise. Water scarcity is a pressing global issue that affects various industries, including biomanufacturing. Implementing water-efficient manufacturing processes and recycling technologies can help alleviate water scarcity concerns while maintaining the production of biopharmaceuticals and other biologically derived products.

Increasing Number of Biopharmaceutical Businesses: During the forecast period, the growth of the next-generation biomanufacturing market is expected to be driven by the increasing number of biopharmaceutical companies worldwide. The need for advanced biomanufacturing to meet patient demands is likely to fuel the progress of the next-generation biomanufacturing industry. The global biopharmaceutical industry has been experiencing substantial growth, driven by advancements in medical science, rising healthcare needs, and the development of novel therapies. As more biopharmaceutical companies emerge and existing ones expand their product pipelines, the demand for efficient, scalable, and technologically advanced biomanufacturing processes to produce these innovative therapies is growing. Overall, the rising number of biopharmaceutical companies and the need to meet patient demands for cutting-edge therapies are driving the progress and growth of the next-generation biomanufacturing industry. As the industry continues to innovate and develop advanced manufacturing solutions, it will play a critical role in shaping the future of healthcare and contributing to improved patient outcomes.

Growing Demand for Biopharmaceuticals: The increasing demand for biopharmaceuticals is a significant driver that is boosting the demand for biomanufacturing. Biopharmaceuticals are a class of drugs produced using living organisms or biological systems, such as bacteria, yeast, mammalian cells, or plant cells. These drugs include monoclonal antibodies, vaccines, gene therapies, cell therapies, and more. The unique nature of biopharmaceuticals and their growing prominence in medical treatments have led to a higher demand for specialized biomanufacturing processes. Biopharmaceuticals have revolutionized the treatment landscape for various diseases, offering targeted therapies with high specificity and reduced side effects. As more biopharmaceuticals enter the market and offer innovative treatment options, the demand for their production increases. The development of new and advanced therapies, such as gene therapies and cell therapies, is contributing to the growing demand for biopharmaceutical manufacturing. These therapies require complex manufacturing processes that involve genetic modification and manipulation of cells, highlighting the need for specialized biomanufacturing expertise.

Key Market Challenges

Huge Capital Expenditure: The biomanufacturing process involves intricate and specialized equipment, facilities, and technologies, which can require significant financial investments. Establishing a biomanufacturing facility or upgrading existing infrastructure demands substantial initial capital investment. This encompasses constructing or renovating specialized cleanrooms, purchasing bioreactors, purification equipment, and other sophisticated tools necessary for biopharmaceutical production. The substantial capital required for biomanufacturing can divert resources away from other critical areas such as research and development, marketing, and business expansion. This challenge in resource allocation can impact a company's overall growth strategy. The high capital expenditure can result in either overestimating or underutilizing manufacturing capacity. If the actual demand for the manufactured product is lower than anticipated, the investment may not yield the expected returns.

Lack of Skilled Professionals: The shortage of skilled professionals is a significant challenge that can hinder the growth of the biomanufacturing market. Biomanufacturing is a highly specialized field that requires expertise in various scientific, engineering, and technical disciplines. The shortage of skilled professionals can impact the efficiency, quality, and capacity of biomanufacturing operations. The complexity of biomanufacturing processes, such as cell culture, fermentation, purification, and quality control, demands specialized expertise. A lack of skilled manpower can lead to delays in production timelines, slowing down the availability of biopharmaceuticals and other biologically derived products in the market. Skilled professionals are vital for maintaining rigorous quality control and assurance throughout the manufacturing process. The absence of skilled professionals can compromise product quality and safety. Skilled professionals also play a crucial role in driving innovation and process improvement within biomanufacturing. The lack of innovation can hinder the adoption of advanced technologies and hinder overall market growth. As the demand for biopharmaceuticals increases, companies may struggle to expand their manufacturing capacity due to the lack of skilled personnel required to manage and operate new facilities.

Key Market Trends

Emergence of Continuous Biomanufacturing: The emergence of continuous biomanufacturing has the potential to significantly boost the growth of the biomanufacturing industry in the future. Continuous biomanufacturing represents a departure from traditional batch processes by enabling seamless, uninterrupted production of biopharmaceuticals and other biologically derived products. This innovative approach offers several benefits that can positively impact efficiency, flexibility, cost-effectiveness, and overall market expansion. Continuous biomanufacturing allows for continuous monitoring and adjustment of process parameters in real-time. This leads to improved process control, reduced variability, and enhanced product consistency, resulting in higher process efficiency and reduced production times. Continuous biomanufacturing systems are generally more compact and require less physical space than traditional batch systems. This reduction in facility footprint can lead to cost savings and greater flexibility in facility design and location. Continuous biomanufacturing can enable higher production capacities by running processes continuously, thereby increasing output without the need for significant facility expansion. This increased capacity can meet the growing demand for biopharmaceuticals and other biologically derived products.

Development Of a Next-Generation Biomanufacturing Process: The advancement of a next-generation biomanufacturing process enables the production of biological medications for critical ailments like liver and kidney disease, cancer, and diabetes. Moreover, the growing adoption of single-use products such as single-use bioreactors and biocontainers, along with increased financial support from private investors and governments for the development of next-generation biomanufacturing units, are key drivers of the global next-generation biomanufacturing market. These trends are expected to persist throughout the forecast period.

Segmental Insights

Application Insights: Monoclonal antibodies are one of the most commonly produced products using biomanufacturing processes. Monoclonal antibodies (mAbs) are therapeutic proteins designed to target specific antigens in the body, such as cancer cells or immune system molecules. They have become integral to modern medical treatment, and their production often involves biomanufacturing techniques. Monoclonal antibodies are widely used in treating diseases including cancer, autoimmune disorders, and infectious diseases. They are produced using biomanufacturing processes that involve culturing mammalian cells to express specific antibodies. Bioreactors and advanced cell culture techniques are commonly used for mAb production. Hormones are the fastest-growing segment as hormones like insulin, growth hormone, and erythropoietin are also produced using biomanufacturing. These therapeutic proteins treat hormonal deficiencies and other medical conditions. Biomanufacturing involves using recombinant DNA technology to insert the hormone gene into host cells (e.g., bacteria or yeast), which then produce the hormone in large quantities. The manufacturing of hormones for rising cases of diabetes and other hormone deficiency-related disorders is expected to boost the demand for biomanufacturing hormones globally.

Workflow Insights: Continuous upstream biomanufacturing allows for continuous and steady production of biopharmaceuticals, eliminating the stop-start nature of traditional batch processes. This can lead to improved process efficiency, reduced downtime, and better resource utilization. The consistent environment and controlled conditions of continuous bioreactors can lead to higher cell densities and improved product yields compared to batch processes. Continuous biomanufacturing systems are often more compact than traditional batch systems, which can help in optimizing facility space and reducing operational costs. Continuous processes can result in more consistent and uniform product quality due to reduced variability and more precise process control.

Regional Insights: North America dominates the market due to its well-developed and advanced healthcare infrastructure, including research institutions, academic centers, and medical facilities. This infrastructure supports biomanufacturing activities and facilitates collaboration between academia, research organizations, and industry players. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have established rigorous but well-defined guidelines for the approval and oversight of biopharmaceutical products. This regulatory expertise provides confidence to both investors and consumers in the safety and quality of bio-manufactured products. North America's strong venture capital ecosystem and financial markets support the funding of biopharmaceutical startups and established companies, fueling innovation and research efforts. The Asia-Pacific region, including China and India, has been experiencing growth in the biomanufacturing sector due to factors like lower manufacturing costs, a large talent pool, and increasing demand for biopharmaceuticals in the region. Some countries actively focus on developing biomanufacturing clusters and infrastructure to attract investments and boost their biopharmaceutical capabilities.

Key Market Players

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• BGI
• PerkinElmer Inc.
• QIAGEN
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.

Report Scope:

In this report, the Global Bio-Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bio-Manufacturing Market, By Workflow:

• Continuous Upstream Biomanufacturing
• Single-Use Upstream Biomanufacturing
• Downstream Biomanufacturing

Bio-Manufacturing Market, By Application:

• Monoclonal Antibodies
• Hormones
• Vaccines
• Recombinant Proteins
• Others

Bio-Manufacturing Market, By End User:

• Biopharmaceutical Companies
• Research Institutions
• CMOs/CDMOs

Bio-Manufacturing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Bio-Manufacturing Market.

Available Customizations:

• Global Bio-Manufacturing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bio-Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing)
  • 5.2.2. By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others)
  • 5.2.3. By End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. North America Bio-Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bio-Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Bio-Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Bio-Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Bio-Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bio-Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Bio-Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Bio-Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Bio-Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Bio-Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Bio-Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bio-Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Bio-Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Prescription Mode
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Bio-Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Bio-Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Bio-Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Bio-Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bio-Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Bio-Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Bio-Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Bio-Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bio-Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Bio-Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Bio-Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Illumina Inc.
  • 15.5.2. Thermo Fischer Scientific Inc.
  • 15.5.3. Oxford Nanopore Technologies plc
  • 15.5.4. Agilent Technologies, Inc.
  • 15.5.5. BGI
  • 15.5.6. PerkinElmer Inc.
  • 15.5.7. QIAGEN
  • 15.5.8. Eurofins Scientific
  • 15.5.9. F. Hoffmann-La Roche Ltd
  • 15.5.10. Takara Bio Inc.

16. Strategic Recommendations

17. About Us & Disclaimer